Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRA-444 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| SRA-444 + Placebo | EXPERIMENTAL | Experimental; Placebo |
| Name | Type | Description |
|---|---|---|
| SRA-444 | DRUG | - |
Inclusion criteria: * Men or women from 60 years of age at screening. * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). Exclusion criteria: * History of drug abuse ...
Top 20 of 30 competitors
SRA-444 is an investigational small molecule being developed by Pfizer, Inc. (PFE) for Alzheimer disease. It is in Phase 1 clinical development and has been studied in two completed Phase 1 trials with a combined enrollment of 106 participants. SRA-444 has not been approved for any indication.
SRA-444 is being studied as a potential treatment for Alzheimer disease. It is an investigational small molecule in Phase 1 development, and its safety, tolerability, and pharmacokinetics have been evaluated in two completed Phase 1 trials. It is not approved for Alzheimer disease or any other indication.
SRA-444 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the Phase 1 clinical trials evaluating SRA-444 in Alzheimer disease.
SRA-444 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and there are currently no active trials. SRA-444 is investigational and has not been approved by the FDA or any other regulatory agency.
SRA-444 has been evaluated in two completed Phase 1 trials: NCT00499200, which studied safety, tolerability, pharmacokinetics, and 5 HT1A receptor occupancy in 42 participants in Sweden, and NCT00452504, a single ascending dose study in 64 healthy subjects in the Netherlands. Both trials are completed.